Table 2. Characteristics of patients with controlled and uncontrolled asthma.
| Variables | Controlled asthma (ACQ score <1.5) | Uncontrolled asthma (ACQ score ≥1.5) | P value |
|---|---|---|---|
| N | 226 | 147 | |
| Agea | 46.8 (14.02) | 48.0 (13.66) | 0.425 |
| Male/Female | 93/133 | 66/81 | 0.475 |
| Smokingc: never | 135/201 (67.2) | 82/141 (58.2) | 0.085 |
| Pack years (ex/current smokers)b | 19.5 (8.0, 41.0) | 19.5 (7.5, 30.0) | 0.321 |
| Atopyc | 58/95 (61.1) | 19/30 (63.3) | 0.823 |
| Pre-β2 agonist spirometrya (N) | 223 | 147 | |
| FEV1% predicted | 75.69 (22.04) | 64.83 (23.90) | <0.0001 |
| FVC % predicted | 90.14 (18.30) | 85.53 (22.84) | 0.045 |
| FEV1/FVC | 69.38 (13.97) | 61.65 (13.76) | <0.0001 |
| Post β2 agonist spirometrya (N) | 194 | 142 | |
| FEV1% predicted | 81.76 (22.13) | 74.35 (24.87) | 0.004 |
| FVC % predicted | 94.42 (17.67) | 93.49 (22.33) | 0.668 |
| FEV1/FVC | 71.64 (14.14) | 64.98 (13.55) | <0.0001 |
| Asthma control | |||
| ACQ6 score | 0.5 (0.17, 1.0) | 2.17 (1.83, 2.83) | <0.0001 |
| Severe refractory asthma (ATS/ERS criteria)c | 9/226 (4.0) | 3/147 (2.0) | 0.378 |
| Severe asthma requiring Step 4/5c | 47/226 (20.8) | 9/147 (6.1) | <0.0001 |
| Exacerbation history | |||
| ≥1 severe exacerbation in past year requiring OCS | 71/225 (31.6) | 61/146 (41.8) | 0.044 |
| Hospital admission | 64/226 (28.3) | 48/147 (32.7) | 0.395 |
| ICU admission | 1/226 (0.4) | 1/147 (0.7) | 1.0 |
| ER visit | 28/224 (12.5) | 19/145 (13.1) | 0.865 |
| Unscheduled doctor visit | 49/225 (21.8) | 50/146 (34.3) | 0.008 |
| Respiratory medications | |||
| OCS usec | 2/226 (0.9) | 4/147 (2.7) | 0.217 |
| ICS/LABA usec | 101/226 (44.7) | 54/146 (37.0) | 0.141 |
| ICS dose (BDPmcg/day)b | 400 (200, 1,000) | 400 (400, 1,000) | 0.609 |
| Long Acting anticholinergicc | 3/226 (1.3) | 5/147 (3.4) | 0.272 |
| Leukotriene modifierc | 56/226 (24.8) | 14/146 (9.6) | <0.0001 |
| Theophyllinec | 43/226 (19.0) | 6/147 (4.0) | <0.0001 |
ACQ, Asthma Control Questionnaire; ATS, American Thoracic Society; BDP, beclomethasone dipropionate; ER, emergency room; ERS, European Respiratory Society; ICS, Inhaled corticosteroid; ICU, intensive care unit; LABA, long-acting beta2-agonist; OCS, oral corticosteroid. Data given as amean (SD), bmedian (Q1, Q2), cNo. (%). Italic face indicates significant.